Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000921895-25-000560·Arbutus Biopharma Corp
Schedule 13D ownership disclosure
Arbutus Biopharma Corp
Common Shares, without par value · CUSIP: 03879J100
Event date: 2025-02-20
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Whitefort Capital Master Fund, LPReported CIK 0001704387
Shares: 13,307,967.00 · Class: 7.0%
- Whitefort Capital GP, LLC
Shares: 13,307,967.00 · Class: 7.0%
- Whitefort Capital Management, LPReported CIK 0001884931
Shares: 13,307,967.00 · Class: 7.0%
- Whitefort Capital Management GP, LLC
Shares: 13,307,967.00 · Class: 7.0%
- David Salanic
Shares: 13,307,967.00 · Class: 7.0%
- Joseph Kaplan
Shares: 13,307,967.00 · Class: 7.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000921895-25-000560
- Form type
- SCHEDULE 13D/A
- Filer
- Arbutus Biopharma Corp
- CIK
- CIK 1447028
- Filed
- Feb 21, 2025
- Reporting period
- Feb 20, 2025
- Description
- Schedule 13D beneficial ownership